Details of the Drug Reposition

General Information of This Drug (ID: DMD1HLC)

Drug Name
Floctafenine   DMD1HLC
Synonyms
floctafenine; 23779-99-9; Idarac; Novodolan; Diralgan; Idalon; 2,3-Dihydroxypropyl 2-((8-(trifluoromethyl)quinolin-4-yl)amino)benzoate; RU 15750; R 4318; Floctafeninum [INN-Latin]; Floctafenina [INN-Spanish]; 8-Trifluoromethyl-7-deschloroglafenine; C20H17F3N2O4; EINECS 245-881-4; BRN 0457808; 2,3-Dihydroxypropyl 2-((8-(trifluoromethyl)-quinolin-4-yl)amino)benzoate; 2,3-Dihydroxypropyl N-(8-(trifluoromethyl)-4-quinolyl)anthranilate; 4-(o-(2',3'-Dihydroxypropyloxycarbonyl)phenyl)-amino-8-trifluoromethylquinoline
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Acute pain DISFGEKX MG31 Approved [1]
------------------------------------------------------------------------------------
1 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Arthritis DIST1YEL FA20 Discontinued in Phase 2 [2]
------------------------------------------------------------------------------------

References

1 Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial). Trials. 2020 Oct 13;21(1):846.
2 ClinicalTrials.gov (NCT00033371) Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis